Mediators of Inflammation

Mediators of Inflammation / 2009 / Article

Research Article | Open Access

Volume 2009 |Article ID 510254 | 7 pages | https://doi.org/10.1155/2009/510254

Local C-Reactive Protein Expression in Obliterative Lesions and the Bronchial Wall in Posttransplant Obliterative Bronchiolitis

Academic Editor: Oreste Gualillo
Received18 Jan 2009
Accepted26 Mar 2009
Published26 May 2009

Abstract

The local immunoreactivity of C-reactive protein (CRP) was studied in a heterotopic porcine model of posttranplant obliterative bronchiolitis (OB). Bronchial allografts and control autografts were examined serially 2–28 days after subcutaneous transplantation. The autografts stayed patent. In the allografts, proliferation of inflammatory cells ( ) and fibroblasts ( ) resulted in occlusion of the bronchial lumens ( ). Influx of CD4+ ( ) and CD8+ ( ) cells demonstrated allograft immune response. CRP positivity simultaneously increased in the bronchial walls ( ), in macrophages, myofibroblasts, and endothelial cells. Local CRP was predictive of features characteristic of OB ( –0.879, .05− ). Early obliterative lesions also showed CRP positivity, but not mature, collagen-rich obliterative plugs ( ). During OB development, CRP is localized in inflammatory cells, myofibroblasts and endothelial cells probably as a part of the local inflammatory response.

1. Introduction

Posttransplant obliterative bronchiolitis (OB) is the major cause of lung allograft dysfunction and late mortality among lung allograft recipients [1]. The registry data indicates that, 5 years after transplantation, 45% of recipients had developed OB [1]. OB is a manifestation of chronic allograft rejection with histopathological features that include subepithelial inflammation, epithelial cell injury, and excessive fibroproliferation, resulting in permanent obliteration of small airways [2]. Long-term success in lung transplantation will only be possible when there is better understanding of the molecular and cellular mechanisms of OB and better strategies for its treatment.

C-reactive protein (CRP) is an acute-phase protein that is predominantly synthesized by hepatocytes in response to inflammation, infection, and tissue damage [3, 4]. Extrahepatic synthesis of CRP was first described in human peripheral blood lymphocytes [5]. Expression in human neurons [6], carotid arterial endothelial cells [7], normal vascular tissue [8], coronary artery smooth muscle cells [9, 10], atherosclerotic plaques [11, 12], and adipocytes [13] has also been reported. In the human respiratory tract, epithelial cells in nasal polyps express CRP [14], as do alveolar macrophages in lung tissue [15].

CRP is used as a clinical marker of acute systemic inflammation. Pulmonary diseases with inflammatory features raise the serum CRP level [16, 17], and there is also evidence of local pulmonary CRP synthesis [18]. Since OB has inflammatory features, we hypothesized that local CRP production could occur in posttransplant OB development. To investigate this hypothesis, we conducted a detailed CRP expression analysis in our porcine model of posttransplant OB [19].

2. Materials and Methods

2.1. Experimental Model

Bronchial segments were transplanted subcutaneously in 11 random-bred unrelated domestic pigs, each weighing 20 kg. The animals received humane care in compliance with the “Principles of Laboratory Animal Care” (NIH publication Vol 25, No. 28 revised 1996) and with all specific national legislation. The protocol was approved by the institution’s Committee for Animal Research and by the South Finland Provincial Administration. Special attention was given to anesthesia and pain relief during surgical procedures.

Animals were anesthetized for surgical procedures as described previously [20] and euthanized with high-dose intravenous sodium pentobarbital at the end of the follow-up. The donor left caudal pulmonary lobe was removed for preparation of implants. A series of bronchial segments, 1.5 cm in length, were subcutaneously transplanted into the ventral side of each recipient. In addition to 6 animals with allograft implants, 5 animals received autograft controls. A total of 190 samples were harvested through small incisions on follow-up days 2, 4, 7, 9, 11, 14, 17, 21 and 28. A portion of each sample (two-thirds) was formalin-fixed and embedded in paraffin, and the rest (one-third) was snap-frozen in liquid nitrogen and stored at until use.

2.2. Histology and Immunocytochemistry

The formalin-fixed sections (4  m) were mounted on Vectabond-coated slides (Vector Labs. Ltd., Peterborough, UK) and processed for histology (hematoxylin and eosin) and immunocytochemistry. Monoclonal mouse antipig antibodies (Sigma Chemical, St.Louis, MO, USA) against vimentin (1 : 1000) α-smooth muscle cell actin (α-SMA) (1 : 16 000) were used as described previously [21], along with standard avidin-biotin-peroxidase techniques [22].

The Frozen sections, 4  m thick, were cut and air-dried onto silane-coated slides, fixed in acetone at for 10 minutes and stored at until use. The 3-layer indirect immunoperoxidase method and monoclonal mouse antibodies detecting swine CD4 and CD8 (VMRD Inc., Pullman, Wash, USA) were used in addition to mouse monoclonal antibodies against human monocytes/macrophages (Oxford Biomarketing, Oxford, UK), also reactive with porcine macrophages, and against human CRP (Abcam Ltd., Cambridge, UK) (1 : 600), also reactive with porcine CRP, as described previously [23]. As a control, nonspecific mouse IgG (Dako A/S, Glostrup, Denmark) was used to stain all sections by an identical protocol.

2.3. Microscopic Assessment

Assessments were performed on 3 separate bronchi from each sample when available. Epithelial loss, luminal obliteration, bronchial wall fibrosis (a pathological increase in connective tissue composed of fibroblasts and extracellular matrix), and inflammation (the number of infiltrating inflammatory cells in the tissue) were graded on a semiquantitative scale. The scale, using scores ranging from 0 to 3, was as follows: 0 = no alteration, 1 = mild alteration, 2 = moderate alteration (pathological alterations equal to normal tissue), and 3 = severe alteration (pathological changes predominant).

CD4+ cells, CD8+ cells, and macrophages were counted in 3 high-power visual fields for each bronchus that was assessed. The percentages of CRP-positive cells in the epithelium and the obliterative plug were counted separately, and the staining intensity was graded on a scale from 0 to 3, where 0 = negative; 1 = positive cells showing weak staining; 2 = more intense and/or irregular staining; 3 = intense, uniform staining. The CRP index was calculated by multiplying the percentage of CRP-positive cells by the CRP staining intensity score, a method we previously used to assess cyclo-oxygenase expression [20]. CRP-positive cells in the bronchial wall were assessed on a scale from 0–3 based on the intensity of immunocytochemical staining and the number of positive cells.

2.4. Statistics

All data are expressed as the mean standard error (SEM). The Mann-Whitney U-test, Z adjusted for ties (Statistica v.5.1, StatSoft Inc., Tulsa, OKla, USA), was used for statistical analysis, with considered statistically significant. Spearman’s rank correlation served for correlation analysis.

3. Results

3.1. Histology

On posttransplant day 2, ischemic damage to the airway epithelium was moderate both in the autograft controls and in the bronchial allografts . Rapid recovery to normal respiratory epithelium occurred in the autografts within 7 days. In allografts, temporary and partial recovery on day 4 turned to rapid loss of the epithelial cells with grade on day 7, when a significant difference was apparent compared to autografts; at this time, most of the preserved epithelium comprised the pure basal cell layer in allografts.

Inflammation in the bronchial wall remained low grade in the autografts (Figure 1). In allografts, the number of inflammatory cells gradually increased, and there was a significant difference compared to autografts from day 4 on. The onset of fibroproliferation in the bronchial wall paralleled the increase in inflammation grade, and fibroproliferation was significantly different in allografts compared to autografts by day 11 (Figure 1). Obliterative lesions gradually occluded the bronchial lumens in allografts, showing a significant difference from autografts from day 7 on (Figure 1). Severe remodeling of the bronchial allografts occurred, while autografts stayed patent with functioning mucus glands.

3.2. Immunocytochemistry

Fibroblasts showed positive staining for vimentin and α-SMA both in the bronchial wall and in the obliterative lesions. Intense positivity for α-SMA was evident in newly formed obliterative plugs, but not in the mature, collagen-rich, scar-like lesions.

In the bronchial wall of the control autografts, a few CD4+ and CD8+ cells were observed throughout follow-up. An influx of CD4+ and CD8+ cells with CD8+ cell predominant indicated an immune response in the bronchial allografts that was significantly different from autografts from day 4 onward (Table 1). The number of macrophages was highest during the initial ischemic injury and at the onset of the immune response; macrophages were present in greater numbers from day 7 onward in allografts, showing a statistically significant difference also on days 9 , 11, 14, 21, and 28 (Figure 1).


Follow-up dayAutograftsAllografts

CD4+ cellsCD8+ cellsCD4+ cellsCD8+ cells
2
4
7
9
11
14
17
21
28

, , .

During the initial ischemic damage on follow-up day 2, 57% of the respiratory epithelial cells in the autografts and 48% in the allografts expressed CRP. The CRP staining intensities were and , and the CRP indexes were and , respectively. CRP expression rapidly decreased in parallel with epithelial damage in the allografts: 16% ( ) of preserved cells had a CRP staining intensity of and a CRP index of on day 7. Moderate to intense epithelial expression of CRP was observed throughout follow-up in the recovered respiratory epithelium of autografts.

CRP expression was observed in all implants in the bronchial wall during initial ischemic damage, and then decreased in the autografts. In contrast, expression rapidly increased in the bronchial allografts (Figure 1). A statistical difference between autografts and allografts was reached on follow-up day 9 ( ). Expression was not only first predominantly observed in macrophages (Figure 1), but also observed in myofibroblasts and endothelial cells (Figure 2). While the number of macrophages decreased towards the end of follow-up, the intensity of their staining increased as did endothelial CRP immunoreactivity. Positive myofibroblasts counted a minority and were observed at the beginning of follow-up. Correlation analysis showed that the grade of CRP staining intensity in the bronchial wall on follow-up days 14, 17, 21, and 28 appeared to be correlated with and predictive of bronchial wall inflammation, the number of CD4+ and CD8+ cells, bronchial wall fibroproliferation and luminal obliteration (Table 2). These are all features that are characteristic of OB.


Mural inflammationCRP/day 14CRP/day 17CRP/day 21CRP/day 28

day 140.658
day 170.8230.900
day 210.8340.5220.720
day 280.8790.5900.6930.716
N of CD4+ cellsCRP/day 14CRP/day 17CRP/day 21CRP/day 28
day 140.764
day 170.6630.815
day 210.4800.5320.669
day 280.4560.5160.5950.551
N of CD8+ cellsCRP/day 14CRP/day 17CRP/day 21CRP/day 28
day 140.487
day 170.7410.874
day 210.5680.6000.672
day 280.5280.4750.6890.591
Mural fibrosisCRP/day 14CRP/day 17CRP/day 21CRP/day 28
day 140.739
day 170.864
day 210.5250.7370.804
day 280.6420.9260.8410.747
Luminal obliterationCRP/day 14CRP/day 17CRP/day 21CRP/day 28
day 140.845
day 170.7950.797
day 210.8130.8100.875
day 280.8110.8480.8680.870

In the early obliterative lesions, the majority of cells including fibroblasts, inflammatory cells, and endothelial cells showed CRP-positivity with 2.0 intensity scores (Figure 1). After day 11, when 72% of the cells in the obliterative plug were CRP-positive, the percentage of cells expressing CRP rapidly decreased. The calculated CRP index was in the early obliterative lesions on day 4, but only in the mature, collagen-rich plugs on day 28. There was a statistically significant difference in the percentage of positive cells and in the CRP index on day 9 compared to day 17 as well on day 14 compared to day 28 . The controls stained negative.

4. Discussion

This study shows that CRP is expressed in the bronchial wall and in obliterative lesions predominantly not only by macrophages but also by myofibroblasts and endothelial cells in posttransplant OB development. Local CRP expression was previously observed in respiratory epithelial cells [14, 24] and in alveolar macrophages [15, 25]. To our knowledge, this is the first report of CRP expression in pulmonary fibroblasts and endothelial cells in the lung.

In our porcine model, OB developed invariably in allografts, while autografts stayed patent, as expected [19, 26]. The histological changes were similar to those seen in human OB [2, 27] and in rodent models [28, 29]. Neovascularization is rapid in the implants [19]; thus, the initial ischemic injury totally recurred within one week in autografts. In addition, partial recovery prior to onset of the immune response was also observed in the allografts. The influx of CD4+ and CD8+ cells was indicative of the cell-mediated immune response [30]. Vimentin and -SMA postitivity indicated myofibroblasts in the fibroproliferatory stage both in the bronchial wall and in the obliterative lesions [31] and macrophages stained positive with specific immunocytochemistry.

CRP expression has previously been reported in corticular tubules and glomerular cells in rejecting kidneys [32]. Measurement of urine CRP in renal transplant recipients is considered a useful tool in the diagnosis of early allograft rejection [33]. CRP also has properties to serve as a sensitive marker of lung injury [25]. However, our study does not support the use of CRP measurement in the lavation fluid as an early marker of OB, because local CRP is also expressed in human lungs in other inflammatory conditions in response to inflammatory stimuli [24, 34]. Similarly, in our study autografts constantly produced CRP in the respiratory epithelium. This probably occurred initially as a response to the ischemic operative injury and later on as a response to the constantly increasing pressure inside the bronchial implants due to intraluminally secreted mucus. We suggest that the epithelial expression of CRP in autografts is characteristic of this model. This was also previously observed in induced nitric oxide synthase and nitrotyrosine expression [35].

Paralleling the immune response in allografts, we observed CRP expression in the bronchial wall in macrophages and also in myofibroblasts and endothelial cells. Alveolar macrophages are known to express CRP [15]. CRP expression has previously been observed also in endothelial cells [7] and smooth muscle-like cells [9, 10]. In the present study, the intensity of staining increased during follow-up in macrophages and endothelial cells, but was observed only in early myofibroblasts as previously in smooth muscle-like cells [7] and in early fibrous plaques [36]. At the end of the follow-up macrophages stained intensely, as did the endothelium of the numerous capillaries. The grade of CRP intensity in the bronchial wall correlated with and was predictive of further inflammation, the number of CD4+ and CD8+ cells, and fibroproliferation, including obliteration of the bronchial lumen. All of these features are characteristic of OB [37]. In autografts, mural CRP production was turned off. However, CRP expression was observed in autografts during the first days of follow-up, when ischemic damage recurred, and subsequent inflammation was established. Endothelial CRP production has been reported in human carotid arteries [7] and in the aorta [38], but it has not previously been reported in lung tissue or in cases of lung allograft rejection. In this study, CRP expression coincided with the remodeling process and with bronchial wall inflammation as it has previously been reported to associate with the progression of atherosclerosis in coronary arteries [36].

Inflammatory cytokines interleukines (ILs) 1 and 6 are stimulatory, but tumor necoris factor (TNF) is an inhibitory cytokine for the liver synthesis of CRP [39]. Local CRP expression is also thought to be a response to inflammatory cytokines [9] which regulate the immune cascade in lung allograft rejection. In renal tubular epithelial cells, TNF- does not stimulate local CRP expression [32], but in human pulmonary epithelial cells, CRP is synthesized in response to cytokines IL6, TNF- , interferon , and IL1 [24]. Adipocytes are also shown to produce CRP under the influence of IL6 and TNF- [13]. Casals et al. suggested that CRP could modulate lung inflammation by decreasing the production of TNF- in alveolar macrophages [25]. We have previously studied TNF- in our model of OB [40]. In the bronchial wall its expression paralleled the immunoreactivity of CRP. TNF- expression seems to decline prior to that of CRP during obliterative airway disease development. This might be a consequence of stimulating influence of the TNF- on CRP expression.

In the early obliterative plug, CRP positivity was observed in the majority of cells. In the mature plug expression declined significantly. Thus, as in atherosclerotic lesions [38], local CRP in the obliterative plaque contributes with plaque activity. In maturing carotid artery plaques, CRP expression is evident in inflammatory cells as well as in the endothelial cells of newly formed microvessels [7]. Our study found CRP expression in early obliterative plugs, but not in the mature, scar-like lesions, in which the existence of α-SMA was also not expressed. The most intense CRP expression was observed during the accelerated inflammatory phase. Thus, it seems that CRP in obliterative plugs is a local inflammatory response, as in atherosclerotic lesions [38].

Inhibition of complement activation in OB development seems to have beneficial effects on graft survival [41]. There is evidence that CRP limits excessive complement activation [42] and reduces complement-mediated damage to host tissue. In addition, CRP and complement components act in concert to promote clearance of apoptotic cells, which prevents necrosis [43]. We have demonstrated that apoptotic cell death is an important mechanism in the process that leads to graft deterioration in OB after lung transplantation [44]. The exact role of CRP in our model of OB remains unresolved. It may be observed that local CRP has a promoting influence on the inflammatory component [45, 46] and also on allograft rejection.

5. Conclusions

This study documents CRP immunoreactivity in posttransplant OB. There are multiple factors leading to chronic lung allograft rejection. CRP expression may be a local response to inflammatory cytokines and may promote the inflammatory component in OB development.

Abbreviations

OB:Obliterative bronchiolitis
CRP:C-reactive protein
α-SMA:α-smooth muscle cell actin
SEM:Standard error
IL:Interleukine
TNF- :Tumor necrosis factor-

Acknowledgments

The authors would like to thank Sisko Litmanen and Pirkko Uhlbäck for excellent technical assistance. The work was supported by research grants from the Helsinki University Hospital Special Funds, the Finnish Anti-Tuberculosis Association Foundation, and the Tampere Tuberculosis Foundation.

References

  1. J. D. Christie, L. B. Edwards, P. Aurora et al., “Registry of the international society for heart and lung transplantation: twenty-fifth official adult lung and heart/lung transplantation report-2008,” Journal of Heart and Lung Transplantation, vol. 27, no. 9, pp. 957–969, 2008. View at: Publisher Site | Google Scholar
  2. M. Estenne and M. I. Hertz, “Bronchiolitis obliterans after human lung transplantation,” American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 4, pp. 440–444, 2002. View at: Publisher Site | Google Scholar
  3. M. B. Pepys and G. M. Hirschfield, “C-reactive protein: a critical update,” The Journal of Clinical Investigation, vol. 111, no. 12, pp. 1805–1812, 2003. View at: Publisher Site | Google Scholar
  4. J. Hurlimann, G. J. Thorbecke, and G. M. Hochwald, “The liver as the site of C-reactive protein formation,” Journal of Experimental Medicine, vol. 123, no. 2, pp. 365–378, 1966. View at: Publisher Site | Google Scholar
  5. A. E. Kuta and L. L. Baum, “C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes,” Journal of Experimental Medicine, vol. 164, no. 1, pp. 321–326, 1986. View at: Publisher Site | Google Scholar
  6. K. Yasojima, C. Schwab, E. G. McGeer, and P. L. McGeer, “Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease,” Brain Research, vol. 887, no. 1, pp. 80–89, 2000. View at: Publisher Site | Google Scholar
  7. J. Krupinski, M. M. Turu, J. Martinez-Gonzalez et al., “Endogenous expression of C-reactive protein is increased in active (ulcerated noncomplicated) human carotid artery plaques,” Stroke, vol. 37, no. 5, pp. 1200–1204, 2006. View at: Publisher Site | Google Scholar
  8. E. E. Diehl, G. K. Haines III, J. A. Radosevich, and L. A. Potempa, “Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue,” American Journal of the Medical Sciences, vol. 319, no. 2, pp. 79–83, 2000. View at: Publisher Site | Google Scholar
  9. P. Calabró, J. T. Willerson, and E. T. H. Yeh, “Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells,” Circulation, vol. 108, no. 16, pp. 1930–1932, 2003. View at: Publisher Site | Google Scholar
  10. W. J. Jabs, E. Theissing, M. Nitschke et al., “Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue,” Circulation, vol. 108, no. 12, pp. 1428–1431, 2003. View at: Publisher Site | Google Scholar
  11. K. Yasojima, C. Schwab, E. G. McGeer, and P. L. McGeer, “Generation of C-reactive protein and complement components in atherosclerotic plaques,” American Journal of Pathology, vol. 158, no. 3, pp. 1039–1051, 2001. View at: Google Scholar
  12. A. M. Wilson, J. D. Swan, H. Ding et al., “Widespread vascular production of C-reactive protein (CRP) and a relationship between serum CRP, plaque CRP and intimal hypertrophy,” Atherosclerosis, vol. 191, no. 1, pp. 175–181, 2007. View at: Publisher Site | Google Scholar
  13. P. Calabro, D. W. Chang, J. T. Willerson, and E. T. H. Yeh, “Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation,” Journal of the American College of Cardiology, vol. 46, no. 6, pp. 1112–1113, 2005. View at: Publisher Site | Google Scholar
  14. J. M. Gould and J. N. Weiser, “Expression of C-reactive protein in the human respiratory tract,” Infection and Immunity, vol. 69, no. 3, pp. 1747–1754, 2001. View at: Publisher Site | Google Scholar
  15. Q. Dong and J. R. Wright, “Expression of C-reactive protein by alveolar macrophages,” Journal of Immunology, vol. 156, no. 12, pp. 4815–4820, 1996. View at: Google Scholar
  16. C. Agustí, A. Rañó, M. Rovira et al., “Inflammatory response associated with pulmonary complications in non-HIV immunocompromised patients,” Thorax, vol. 59, no. 12, pp. 1081–1088, 2004. View at: Publisher Site | Google Scholar
  17. N. J. M. Cano, C. Pichard, H. Roth et al., “C-reactive protein and body mass index predict outcome in end-stage respiratory failure,” Chest, vol. 126, no. 2, pp. 540–546, 2004. View at: Publisher Site | Google Scholar
  18. C. Casals, A. Varela, M. L. F. Ruano et al., “Increase of C-reactive protein and decrease of surfactant protein A in surfactant after lung transplantation,” American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 1, pp. 43–49, 1998. View at: Google Scholar
  19. M. H. Uusitalo, U.-S. Salminen, T. S. Ikonen et al., “Alloimmune injury preceding airway obliteration in porcine heterotopic lung implants: a histologic and immunohistologic study,” Transplantation, vol. 68, no. 7, pp. 970–975, 1999. View at: Publisher Site | Google Scholar
  20. O. E. Päiväniemi, P. K. Maasilta, H. S. Alho, C. H. J. Wolff, and U.-S. Salminen, “Cyclooxygenase-2 expression in experimental post-transplant obliterative bronchiolitis,” Journal of Pathology, vol. 204, no. 3, pp. 340–348, 2004. View at: Publisher Site | Google Scholar
  21. L. M. Eerola, H. S. Alho, P. K. Maasilta et al., “Matrix metalloproteinase induction in post-transplant obliterative bronchiolitis,” Journal of Heart and Lung Transplantation, vol. 24, no. 4, pp. 426–432, 2005. View at: Publisher Site | Google Scholar
  22. S. Shu, G. Ju, and L. Fan, “The glucose oxidase-DAB-nickel method in peroxidase histochemistry of the nervous system,” Neuroscience Letters, vol. 85, no. 2, pp. 169–171, 1988. View at: Publisher Site | Google Scholar
  23. P. K. Maasilta, T. L. S. Vainikka, H. S. Alho, and U.-S. Salminen, “Immune cells in a heterotopic lamb-to-pig bronchial xenograft model,” Transplant International, vol. 18, no. 9, pp. 1100–1108, 2005. View at: Publisher Site | Google Scholar
  24. L. Ramage, L. Proudfoot, and K. Guy, “Expression of C-reactive protein in human lung epithelial cells and upregulation by cytokines and carbon particles,” Inhalation Toxicology, vol. 16, no. 9, pp. 607–613, 2004. View at: Publisher Site | Google Scholar
  25. C. Casals, J. Arias-Díaz, F. Valiño et al., “Surfactant strengthens the inhibitory effect of C-reactive protein on human lung macrophage cytokine release,” American Journal of Physiology, vol. 284, no. 3, pp. L466–L472, 2003. View at: Google Scholar
  26. U.-S. Salminen, P. K. Maasilta, E. I. Taskinen, H. S. Alho, T. S. Ikonen, and A. L. J. Harjula, “Prevention of small airway obliteration in a swine heterotopic lung allograft model,” Journal of Heart and Lung Transplantation, vol. 19, no. 2, pp. 193–206, 2000. View at: Publisher Site | Google Scholar
  27. H. Luckraz, M. Goddard, K. McNeil, C. Atkinson, L. D. Sharples, and J. Wallwork, “Is obliterative bronchiolitis in lung transplantation associated with microvascular damage to small airways?” Annals of Thoracic Surgery, vol. 82, no. 4, pp. 1212–1218, 2006. View at: Publisher Site | Google Scholar
  28. J. M. Tikkanen, M. Hollmén, A. I. Nykänen, J. Wood, P. K. Koskinen, and K. B. Lemström, “Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease,” American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 10, pp. 1145–1152, 2006. View at: Publisher Site | Google Scholar
  29. S. Garantziotis, S. M. Palmer, L. D. Snyder et al., “Alloimmune lung injury induced by local innate immune activation through inhaled lipopolysaccharide,” Transplantation, vol. 84, no. 8, pp. 1012–1019, 2007. View at: Publisher Site | Google Scholar
  30. N. Qu, A. de Haan, M. C. Harmsen, F. G. M. Kroese, L. F. M. H. de Leij, and J. Prop, “Specific immune responses against airway epithelial cells in a transgenic mouse-trachea transplantation model for obliterative airway disease,” Transplantation, vol. 76, no. 7, pp. 1022–1028, 2003. View at: Publisher Site | Google Scholar
  31. K. Ohta, R. L. Mortenson, R. A. Clark, N. Hirose, and T. E. King Jr., “Immunohistochemical identification and characterization of smooth muscle-like cells in idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 152, no. 5, part 1, pp. 1659–1665, 1995. View at: Google Scholar
  32. W. J. Jabs, B. A. Lögering, P. Gerke et al., “The kidney as a second site of human C-reactive protein formation in vivo,” European Journal of Immunology, vol. 33, no. 1, pp. 152–161, 2003. View at: Publisher Site | Google Scholar
  33. J. Steinhoff, G. Einecke, C. Niederstadt et al., “Renal graft rejection or urinary tract infection? The value of myeloperoxidase, C-reactive protein, and a2-macroglobulin in the urine,” Transplantation, vol. 64, no. 3, pp. 443–447, 1997. View at: Google Scholar
  34. D. Stolz, A. Stulz, B. Müller, A. Gratwohl, and M. Tamm, “BAL neutrophils, serum procalcitonin, and C-reactive protein to predict bacterial infection in the immunocompromised host,” Chest, vol. 132, no. 2, pp. 504–514, 2007. View at: Publisher Site | Google Scholar
  35. U.-S. Salminen, P. K. Maasilta, A. L. J. Harjula, H. M. Romanska, A. E. Bishop, and J. M. Polak, “Nitric oxide in the development of obliterative bronchiolitis in a heterotopic pig model,” Transplantation, vol. 73, no. 11, pp. 1724–1729, 2002. View at: Publisher Site | Google Scholar
  36. S. Norja, L. Nuutila, P. J. Karhunen, and S. Goebeler, “C-reactive protein in vulnerable coronary plaques,” Journal of Clinical Pathology, vol. 60, no. 5, pp. 545–548, 2007. View at: Publisher Site | Google Scholar
  37. L. P. Nicod, “Mechanisms of airway obliteration after lung transplantation,” Proceedings of the American Thoracic Society, vol. 3, no. 5, pp. 444–449, 2006. View at: Publisher Site | Google Scholar
  38. S. K. Venugopal, S. Devaraj, and I. Jialal, “Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects,” American Journal of Pathology, vol. 166, no. 4, pp. 1265–1271, 2005. View at: Google Scholar
  39. S. H. Yap, H. J. Moshage, B. P. C. Hazenberg et al., “Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes,” Biochimica et Biophysica Acta, vol. 1091, no. 3, pp. 405–408, 1991. View at: Publisher Site | Google Scholar
  40. H. S. Alho, P. K. Maasilta, A. L. Harjula, P. Hämmäinen, J. Salminen, and U.-S. Salminen, “Tumor necrosis factor-α in a porcine bronchial model of obliterative bronchiolitis,” Transplantation, vol. 76, no. 3, pp. 516–523, 2003. View at: Publisher Site | Google Scholar
  41. E. A. Kallio, K. B. Lemström, P. J. Häyry, U. S. Ryan, and P. K. Koskinen, “Blockade of complement inhibits obliterative bronchiolitis in rat tracheal allografts,” American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 4, part 1, pp. 1332–1339, 2000. View at: Google Scholar
  42. A. P. Sjöberg, L. A. Trouw, F. D. G. McGrath, C. E. Hack, and A. M. Blom, “Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of C4b-binding protein,” Journal of Immunology, vol. 176, no. 12, pp. 7612–7620, 2006. View at: Google Scholar
  43. D. Gershov, S. Kim, N. Brot, and K. B. Elkon, “C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity,” Journal of Experimental Medicine, vol. 192, no. 9, pp. 1353–1364, 2000. View at: Publisher Site | Google Scholar
  44. H. S. Alho, U.-S. Salminen, P. K. Maasilta, P. Pääkkö, and A. L. J. Harjula, “Epithelial apoptosis in experimental obliterative airway disease after lung transplantation,” Journal of Heart and Lung Transplantation, vol. 22, no. 9, pp. 1014–1022, 2003. View at: Publisher Site | Google Scholar
  45. V. Pasceri, J. T. Willerson, and E. T. H. Yeh, “Direct proinflammatory effect of C-reactive protein on human endothelial cells,” Circulation, vol. 102, no. 18, pp. 2165–2168, 2000. View at: Google Scholar
  46. E. T. H. Yeh, H. V. Anderson, V. Pasceri, and J. T. Willerson, “C-reactive protein: linking inflammation to cardiovascular complications,” Circulation, vol. 104, no. 9, pp. 974–975, 2001. View at: Google Scholar

Copyright © 2009 Outi E. Päiväniemi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

671 Views | 263 Downloads | 6 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.